CROSSJECT - CLINICAL DEMONSTRATION OF ZENEO® EFFICIENCY FOR INTRAMUSCULAR INJECTION OF MIDAZOLAM
November 02 2022 - 3:00AM
CROSSJECT - CLINICAL DEMONSTRATION OF ZENEO® EFFICIENCY FOR
INTRAMUSCULAR INJECTION OF MIDAZOLAM
Press release
CLINICAL DEMONSTRATION OF ZENEO®
EFFICIENCY FOR INTRAMUSCULAR INJECTION OF MIDAZOLAM
• Primary endpoints met
and results in line with
expectations• No impact of clothing on the
intramuscular injection with ZENEO®
Dijon, November 2, 2022 at 8am
CROSSJECT (ISIN: FR0011716265;
Mnémo: ALCJ), a specialty
pharma company that is developing and will soon be
marketing a portfolio of drug / device combinations for use in
emergency situations, is releasing positive headline
results of its clinical study with ZENEO® midazolam. The 4-period,
crossover and randomized study was conducted on 40 healthy
subjects, with gender, ethnicity and BMI1 diversity (ref
ClinicalTrials.gov Identifier NCT05026567).
The primary objective was met. It was the
evaluation of the relative bioavailability of midazolam after
injection with the needle-free autoinjector ZENEO® (10mg midazolam
in 0.625mL) compared to injection of DORMICUM® (10mg midazolam in
2mL) by a conventional syringe with a 30mm needle, into the thigh
on bare skin. The bioequivalence was achieved both on Cmax2 and on
AUC3, with no change of Tmax4. The 90% Confidence Intervals were
respectively of [84-98] for Cmax ratio, and [100-108] for AUC
ratio.
No serious adverse events were reported, and
there was no difference in safety profile between the tested
conditions. Only 2 subjects dropped out before their fourth and
last injection, not for safety but for personal reason.
As secondary objectives, the study aimed to test
the intramuscular injection of midazolam with ZENEO® into thigh
through clothing, compared to injection into thigh on bare skin
with ZENEO® and with DORMICUM®. The 90% Confidence Intervals were
respectively of [87-101] and [79-92] for Cmax ratios, and [87-95]
and [91-98] for AUC ratios, with no change in Tmax. These results
allow considering a much faster emergency treatment, without having
to remove patient’s clothing in an epileptic seizure situation.
In addition, an intramuscular injection with
ZENEO® midazolam in the ventrogluteal site was shown to be
bioequivalent to an injection in the thigh on bare skin either with
a conventional syringe or with ZENEO®.
Finally, ZENEO® and the syringe with
intramucular needle showed a similar and low inter-subject
variability of midazolam pharmacokinetics. This is an additional
demonstration that an injection with ZENEO reached the muscle in
the same way as an injection with a syringe and a 30 mm needle.
As a summary, the outcomes of this
clinical study are a great achievement for
Crossject, as they
demonstrate the effectiveness of an
intramuscular injection with the needle-free autoinjector
ZENEO® into thigh
with or without clothing,
as well as into the
ventrogluteal site.
Contacts :
CrossjectPatrick Alexandre info@crossject.com |
Relations investisseurs
AeliumJérôme Gacoin +33 (0)1 75 77 54 67
crossject@aelium.fr |
|
Relations presse Buzz &
Compagnie Mélanie Voisard +33 (0)3 80 43 54 89
melanie.voisard@buzzetcompagnie.com Christelle
Distinguin +33 (0)6 09 96 51
70christelle.distinguin@buzzetcompagnie.com |
About CROSSJECT • www.crossject.com
CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ;
LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a
portfolio of drugs dedicated to emergency situations: epilepsy,
overdose, allergic shock, severe migraine and asthma attack. Thanks
to its patented needlefree self-injection system, Crossject aims to
become the world leader in self-administered emergency drugs. The
company has been listed on the Euronext Growth market in Paris
since 2014; it receives funding from the United States BARDA
(Biomedical Advanced Research and Development Authority) and from
Bpifrance.
1 BMI : Body Mass Index, a measure of a
person's thickness or thinness2 Cmax: maximum blood
Concentration of the drug3 AUC : Area Under the Curve
reflecting blood levels of a drug over time, an indication of the
dose received4 Tmax : time to reach Cmax
- PR_CROSSJECT_Clinical_demo_ZENEO 01112022
Crossject (EU:ALCJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Crossject (EU:ALCJ)
Historical Stock Chart
From Apr 2023 to Apr 2024